Skip to main content
Erschienen in: Breast Cancer 4/2020

05.03.2020 | Original Article

Behavior of Japanese women after being informed about the benefits and disadvantages of breast cancer screening: a questionnaire survey

verfasst von: Yuka Goto, Koichiro Tsugawa, Yuko Furuya, Miwako Maezato, Yoshimi Tagami, Yuri Ogawa, Misako Saisu, Memi Yamazaki, Fuyumi Kuramochi

Erschienen in: Breast Cancer | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The US Preventative Services Task Force assessed the efficacy of breast cancer screening according to the sum of its benefits and disadvantages. We estimate that the balance of the benefits and disadvantages varies among women depending on their demographic background.

Methods

Between March 2016 and March 2017, we conducted a questionnaire survey among Japanese women who underwent population-based or opportunistic breast cancer screening at our multicenter institutions. We investigated the behavior modification among women after being informed about the benefits and disadvantages of breast cancer screening depending on their demographic background.

Results

Out of 3032 questionnaires that were returned, 2936 (96.8%) were evaluated. The percentage of women with prior knowledge about the benefits and disadvantages of breast cancer screening before reading the leaflets that we created was 24%. However, 95% of the women were willing to undergo screening next time, despite knowing the disadvantages. Regarding overdiagnosis, the young women tended to choose usual treatment, and the elderly women tended to choose active surveillance. In response to the question on the significance of screening, the young women wished to avoid death by breast cancer; whereas, the elderly women wished to live a safe life.

Conclusion

Our results indicate that the information of disadvantages does not lead to a reduction in screening rates. Additionally, we found that the balance between the benefits and disadvantages of breast cancer screening varies among women depending on their demographic background, especially age.
Literatur
1.
Zurück zum Zitat US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716–26.CrossRef US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716–26.CrossRef
2.
Zurück zum Zitat Japanese Breast Cancer Society. Breast cancer treatment guideline for patients 2015. Tokyo: Kanehara Shoten; 2015 (in Japanese). Japanese Breast Cancer Society. Breast cancer treatment guideline for patients 2015. Tokyo: Kanehara Shoten; 2015 (in Japanese).
3.
Zurück zum Zitat Ohuchi N, Ishida Y, Kawai M, Narikawa Y, Yamamoto S, Sobue T. Randomized controlled trial on effectiveness of ultrasonography screening for breast cancer in women aged 40–49 (J-START): research design. Jpn J Clin Oncol. 2010;41:275–7.CrossRef Ohuchi N, Ishida Y, Kawai M, Narikawa Y, Yamamoto S, Sobue T. Randomized controlled trial on effectiveness of ultrasonography screening for breast cancer in women aged 40–49 (J-START): research design. Jpn J Clin Oncol. 2010;41:275–7.CrossRef
4.
Zurück zum Zitat Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366.CrossRef Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366.CrossRef
5.
Zurück zum Zitat Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998–2005.CrossRef Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998–2005.CrossRef
6.
Zurück zum Zitat De Gelder R, Heijnsdijk EAM, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev. 2011;33:111–21.CrossRef De Gelder R, Heijnsdijk EAM, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev. 2011;33:111–21.CrossRef
7.
Zurück zum Zitat Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer. 2009;45:3166–71.CrossRef Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer. 2009;45:3166–71.CrossRef
8.
Zurück zum Zitat Junod B, Zahl P-H, Kaplan RM, Olsen J, Greenland S. An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts. BMC Cancer. 2011;11:401.CrossRef Junod B, Zahl P-H, Kaplan RM, Olsen J, Greenland S. An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts. BMC Cancer. 2011;11:401.CrossRef
9.
Zurück zum Zitat Zahl P-H, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ. 2004;328:921–4.CrossRef Zahl P-H, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ. 2004;328:921–4.CrossRef
10.
Zurück zum Zitat Brodersen J, Siersma VD. Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med. 2013;11:106–15.CrossRef Brodersen J, Siersma VD. Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med. 2013;11:106–15.CrossRef
11.
Zurück zum Zitat Baum M. Harms from breast cancer screening outweigh benefits if death caused by treatment is included. BMJ. 2013;346:f385.CrossRef Baum M. Harms from breast cancer screening outweigh benefits if death caused by treatment is included. BMJ. 2013;346:f385.CrossRef
13.
Zurück zum Zitat Thornton H. Pairing accountability with responsibility: the consequences of screening ‘promotion’. Med Sci Monit. 2001;7:531–3.PubMed Thornton H. Pairing accountability with responsibility: the consequences of screening ‘promotion’. Med Sci Monit. 2001;7:531–3.PubMed
14.
Zurück zum Zitat Hersch J, Barratt A, Jansen J, Houssami N, Irwig L, Jacklyn G, et al. The effect of information about the benefits and harms of mammography on women’s decision-making: study protocol for a randomized controlled trial. BMJ Open. 2014;4:e004990.CrossRef Hersch J, Barratt A, Jansen J, Houssami N, Irwig L, Jacklyn G, et al. The effect of information about the benefits and harms of mammography on women’s decision-making: study protocol for a randomized controlled trial. BMJ Open. 2014;4:e004990.CrossRef
15.
Zurück zum Zitat Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, Howard K, et al. Women’s views on overdiagnosis in breast cancer screening: a qualitative study. BMJ. 2013;346:f158.CrossRef Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, Howard K, et al. Women’s views on overdiagnosis in breast cancer screening: a qualitative study. BMJ. 2013;346:f158.CrossRef
16.
Zurück zum Zitat Waller J, Douglas E, Whitaker KL, Wardle J. Women’s responses to information about overdiagnosis in the UK breast cancer screening programme: a qualitative study. BMJ Open. 2013;3:e002703.CrossRef Waller J, Douglas E, Whitaker KL, Wardle J. Women’s responses to information about overdiagnosis in the UK breast cancer screening programme: a qualitative study. BMJ Open. 2013;3:e002703.CrossRef
18.
Zurück zum Zitat Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is breast cancer the same disease in Asia and Western countries? World J Surg. 2010;34:2308–24.CrossRef Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is breast cancer the same disease in Asia and Western countries? World J Surg. 2010;34:2308–24.CrossRef
19.
Zurück zum Zitat Crystal P, Strano SD, Shcharynski S, Koretz MJ. Using sonography to screen women with mammographically dense breasts. AJR. 2003;181:177–82.CrossRef Crystal P, Strano SD, Shcharynski S, Koretz MJ. Using sonography to screen women with mammographically dense breasts. AJR. 2003;181:177–82.CrossRef
21.
Zurück zum Zitat Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108:2205–40.CrossRef Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108:2205–40.CrossRef
22.
Zurück zum Zitat Etzioni R, Gulati R, Mallinger L, Mondelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med. 2013;158:831–8.CrossRef Etzioni R, Gulati R, Mallinger L, Mondelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med. 2013;158:831–8.CrossRef
23.
Zurück zum Zitat Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women’s attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey. BMJ. 2000;320:1635–40.CrossRef Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women’s attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey. BMJ. 2000;320:1635–40.CrossRef
24.
Zurück zum Zitat Gummersbach E, in der Schmitten J, Mortsiefer A, Abholz HH, Wegscheider K, Pentzek M. Willingness to participate in mammography screening: a randomized controlled questionnaire study of responses to two patient information leaflets with different factual content. Dtsch Arztebl Int. 2015;112:61–8.PubMedPubMedCentral Gummersbach E, in der Schmitten J, Mortsiefer A, Abholz HH, Wegscheider K, Pentzek M. Willingness to participate in mammography screening: a randomized controlled questionnaire study of responses to two patient information leaflets with different factual content. Dtsch Arztebl Int. 2015;112:61–8.PubMedPubMedCentral
25.
Zurück zum Zitat Takayoshi U. The need for supplemental breast cancer screening modalities: a perspective of population-based breast cancer screening programs in Japan. Breast Cancer. 2017;24(1):26–31.CrossRef Takayoshi U. The need for supplemental breast cancer screening modalities: a perspective of population-based breast cancer screening programs in Japan. Breast Cancer. 2017;24(1):26–31.CrossRef
Metadaten
Titel
Behavior of Japanese women after being informed about the benefits and disadvantages of breast cancer screening: a questionnaire survey
verfasst von
Yuka Goto
Koichiro Tsugawa
Yuko Furuya
Miwako Maezato
Yoshimi Tagami
Yuri Ogawa
Misako Saisu
Memi Yamazaki
Fuyumi Kuramochi
Publikationsdatum
05.03.2020
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 4/2020
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-020-01071-6

Weitere Artikel der Ausgabe 4/2020

Breast Cancer 4/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.